Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Risk Factor Gene For Rheumatoid Arthritis Identified By Researchers
Scientists at The Feinstein Institute for Medical Research and a team of collaborators from across the country have identified a new risk factor gene for rheumatoid arthritis. The paper will be published in Nature Genetics and the finding brings light to the nature of the disease. The gene, dubbed REL, is a member of the NF-íºB family, important transcription factors that have many roles in the body. The NF-íºB family seems to have a big hand in regulating the body"s immune response as well.
generic viagra online
Genes And The Environment Interact To Influence Adolescent Alcohol Use
Adolescent alcohol use and behavior problems are influenced by a combination of genetic and environmental factors. A new study has found that socio-regional factors moderate the importance of genetic influences on early adolescent behavior problems in a way that parallels moderating effects observed for alcohol use later in adolescence.
News of the day
Team Preop Briefing Improves Communication, Reduces Errors
A short, preoperative team briefing prior to cardiac surgery - where each person on the team speaks - improves communication and reduces errors and costs, according to a pilot study conducted at Mayo Clinic.
Public Health

Mesoblast Announce Heart Muscle Function Improved After Single, Lowest-Dose Injection Of "Off-The-Shelf" Stem Cells In Patients With Heart Failure

Australia"s regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), announced positive three-month interim efficacy results from the first 20 patients enrolled in the Phase 2 heart failure trial of the proprietary allogeneic, or "off-the-shelf", adult stem cell product Revascor(TM). Three months after receiving a single injection into damaged heart muscle of the lowest dose of Revascor(TM), patients with moderate-severe congestive heart failure demonstrated significantly improved heart muscle function. The randomised, placebo-controlled Phase 2 trial is being run at multiple centres in the United States by Mesoblast"s United States-based associated company Angioblast Systems Inc. The trial aims to compar! e one of three increasing doses of Revascor(TM) against standa! rd of ca re in up to 60 patients suffering from moderate-severe congestive heart failure, defined as a baseline ejection fraction (EF) 40% or lower by echocardiogram. On the basis of the positive interim efficacy results and the excellent safety profile seen to date in the first group of patients receiving the lowest dose of Revascor(TM), the second group of patients set to receive the next higher dose is currently in active recruitment. In the first 20-patient cohort, 15 were randomised to receive the lowest dose of Revascor(TM) and 5 were randomised to the control arm. While control patients with baseline EF 40 or below demonstrated an 11% mean decrease in EF over the first 3 months (mean EF values decreased from 31 to 27), patients with baseline EF 40 or below who received a single injection into damaged heart muscle of the lowest dose of Revascor(TM) showed a 37% mean increase in EF over this period (mean EF increased from 28 to 37, p=0.017). The 10-point me! an difference in absolute EF at three months between cell-treated and control patients was significant (pMesoblast Limited


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009